This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dahut, W. L. Articles by Figg, W. D. Search for Related Content PubMed PubMed Citation Articles by Dahut, W. L. Articles by Figg, W. D. Related Articles Related Correspondence Social Bookmarking                            What's this?

Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer

From the Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Address reprint requests to William D. Figg, Pharm D, National Cancer Institute, 10 Center Dr, Building 10, Room 5A-01, Bethesda, MD 20892; e-mail: wdfigg{at}helix.nih.gov

PURPOSE: Both docetaxel and thalidomide have demonstrated activity in androgen-independent prostate cancer (AIPC). We compared the efficacy of docetaxel to docetaxel plus thalidomide in patients with AIPC.

METHODS: Seventy-five patients with chemotherapy-naïve metastatic AIPC were randomly assigned to receive either docetaxel 30 mg/m² intravenously every week for 3 consecutive weeks, followed by a 1-week rest period (n = 25); or docetaxel at the same dose and schedule, plus thalidomide 200 mg orally each day (n = 50). Prostate-specific antigen (PSA) consensus criteria and radiographic scans were used to determine the proportion of patients with a PSA decline, and time to progression.

RESULTS: After a median potential follow-up time of 26.4 months, the proportion of patients with a greater than 50% decline in PSA was higher in the docetaxel/thalidomide group (53% in the combined group, 37% in docetaxel-alone arm). The median progression-free survival in the docetaxel group was 3.7 months and 5.9 months in the combined group (P = .32). At 18 months, overall survival in the docetaxel group was 42.9% and 68.2% in the combined group. Toxicities in both groups were manageable after administration of prophylactic low-molecular-weight heparin in the combination group.

CONCLUSION: In this randomized phase II trial, the addition of thalidomide to docetaxel resulted in an encouraging PSA decline rate and overall median survival rate in patients with metastatic AIPC. After the prophylactic low-molecular-weight heparin was instituted to prevent venous thromboses, the combination regimen was well tolerated. Larger randomized trials are warranted to assess the impact of this combination.

Supported by the Intramural Program of the National Cancer Institute, Bethesda, MD.

Authors' disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Inhibition of Angiogenesis: Thalidomide or Low-Molecular-Weight Heparin?
  Metin Ozkan, Bulent Eser, Ozlem Er, Gamze Gokoz Dogu, and Mustafa Altinbas
  JCO 2005 23: 2113 [Full Text]

This article has been cited by other articles:

				E. Efstathiou and C. J. Logothetis A New Therapy Paradigm for Prostate Cancer Founded on Clinical Observations Clin. Cancer Res., February 15, 2010; 16(4): 1100 - 1107. [Abstract] [Full Text] [PDF]

				M. Kohli and D. J. Tindall New Developments in the Medical Management of Prostate Cancer Mayo Clin. Proc., January 1, 2010; 85(1): 77 - 86. [Abstract] [Full Text] [PDF]

				E. Efstathiou, J. Kim, and C. J. Logothetis Informative Clinical Investigation: A Demanding Taskmaster J. Clin. Oncol., October 20, 2009; 27(30): 4937 - 4938. [Full Text] [PDF]

				M. Zangari, L. M. Fink, F. Elice, F. Zhan, D. M. Adcock, and G. J. Tricot Thrombotic Events in Patients With Cancer Receiving Antiangiogenesis Agents J. Clin. Oncol., October 10, 2009; 27(29): 4865 - 4873. [Abstract] [Full Text] [PDF]

				W. L. Dahut, J. B. Aragon-Ching, S. Woo, T. M. Tohnya, J. L. Gulley, P. M. Arlen, J. J. Wright, J. Ventiz, and W. D. Figg Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer J. Clin. Pharmacol., June 1, 2009; 49(6): 650 - 660. [Abstract] [Full Text] [PDF]

				S. R. Nalluri, D. Chu, R. Keresztes, X. Zhu, and S. Wu Risk of Venous Thromboembolism With the Angiogenesis Inhibitor Bevacizumab in Cancer Patients: A Meta-analysis JAMA, November 19, 2008; 300(19): 2277 - 2285. [Abstract] [Full Text] [PDF]

				W. D. Stein, W. D. Figg, W. Dahut, A. D. Stein, M. B. Hoshen, D. Price, S. E. Bates, and T. Fojo Tumor Growth Rates Derived from Data for Patients in a Clinical Trial Correlate Strongly with Patient Survival: A Novel Strategy for Evaluation of Clinical Trial Data Oncologist, October 1, 2008; 13(10): 1046 - 1054. [Abstract] [Full Text] [PDF]

				T. M. Sissung, C. E. Baum, J. Deeken, D. K. Price, J. Aragon-Ching, S. M. Steinberg, W. Dahut, A. Sparreboom, and W. D. Figg ABCB1 Genetic Variation Influences the Toxicity and Clinical Outcome of Patients with Androgen-Independent Prostate Cancer Treated with Docetaxel Clin. Cancer Res., July 15, 2008; 14(14): 4543 - 4549. [Abstract] [Full Text] [PDF]

				A. Hamada, T. Sissung, D. K. Price, R. Danesi, C. H. Chau, N. Sharifi, D. Venzon, K. Maeda, K. Nagao, A. Sparreboom, et al. Effect of SLCO1B3 Haplotype on Testosterone Transport and Clinical Outcome in Caucasian Patients with Androgen-Independent Prostatic Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3312 - 3318. [Abstract] [Full Text] [PDF]

				J. A. Garcia, E. A. Klein, C. Magi-Galluzzi, P. Elson, P. Triozzi, and R. Dreicer Clinical and Biological Effects of Neoadjuvant Sargramostim and Thalidomide in Patients with Locally Advanced Prostate Carcinoma Clin. Cancer Res., May 15, 2008; 14(10): 3052 - 3059. [Abstract] [Full Text] [PDF]

				C. J. Logothetis, N. M. Navone, and S.-H. Lin Understanding the Biology of Bone Metastases: Key to the Effective Treatment of Prostate Cancer Clin. Cancer Res., March 15, 2008; 14(6): 1599 - 1602. [Abstract] [Full Text] [PDF]

				S. H. Hwang, A. Rait, K. F. Pirollo, Q. Zhou, V. M. Yenugonda, G. M. Chinigo, M. L. Brown, and E. H. Chang Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue Mol. Cancer Ther., March 1, 2008; 7(3): 559 - 568. [Abstract] [Full Text] [PDF]

				W. L. Dahut, C. Scripture, E. Posadas, L. Jain, J. L. Gulley, P. M. Arlen, J. J. Wright, Y. Yu, L. Cao, S. M. Steinberg, et al. A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer Clin. Cancer Res., January 1, 2008; 14(1): 209 - 214. [Abstract] [Full Text] [PDF]

				T. M. Sissung, R. Danesi, D. K. Price, S. M. Steinberg, R. de Wit, M. Zahid, N. Gaikwad, E. Cavalieri, W. L. Dahut, D. L. Sackett, et al. Association of the CYP1B1*3 allele with survival in patients with prostate cancer receiving docetaxel Mol. Cancer Ther., January 1, 2008; 7(1): 19 - 26. [Abstract] [Full Text] [PDF]

				H. Hung Bevacizumab plus 5-fluorouracil induce growth suppression in the CWR-22 and CWR-22R prostate cancer xenografts Mol. Cancer Ther., August 1, 2007; 6(8): 2149 - 2157. [Abstract] [Full Text] [PDF]

				E. Efstathiou, P. Troncoso, S. Wen, K.-A. Do, C. A. Pettaway, L. L. Pisters, T. J. McDonnell, and C. J. Logothetis Initial Modulation of the Tumor Microenvironment Accounts for Thalidomide Activity in Prostate Cancer Clin. Cancer Res., February 15, 2007; 13(4): 1224 - 1231. [Abstract] [Full Text] [PDF]

				C. P. Tarassoff, P. M. Arlen, and J. L. Gulley Therapeutic vaccines for prostate cancer. Oncologist, May 1, 2006; 11(5): 451 - 462. [Abstract] [Full Text] [PDF]

				P. M. Arlen, J. L. Gulley, C. Parker, L. Skarupa, M. Pazdur, D. Panicali, P. Beetham, K. Y. Tsang, D. W. Grosenbach, J. Feldman, et al. A Randomized Phase II Study of Concurrent Docetaxel Plus Vaccine Versus Vaccine Alone in Metastatic Androgen-Independent Prostate Cancer Clin. Cancer Res., February 15, 2006; 12(4): 1260 - 1269. [Abstract] [Full Text] [PDF]

				W. Berry and M. Eisenberger Achieving Treatment Goals for Hormone-Refractory Prostate Cancer with Chemotherapy Oncologist, October 1, 2005; 10(suppl_3): 30 - 39. [Abstract] [Full Text] [PDF]

				M. Ozkan, B. Eser, O. Er, G. G. Dogu, and M. Altinbas Inhibition of Angiogenesis: Thalidomide or Low-Molecular-Weight Heparin? J. Clin. Oncol., March 20, 2005; 23(9): 2113 - 2113. [Full Text] [PDF]

				W. D. Figg, A. Retter, S. M. Steinberg, and W. L. Dahut In Reply: J. Clin. Oncol., March 20, 2005; 23(9): 2113 - 2114. [Full Text] [PDF]